Have looked at the charts for UUUU and IBRX and the price momentum oscillator I follow has turned up on both which should help. The small pharma and biotechs as a group have been pummeled to prices that are less than the cash/share on their books in many cases. So, moves are more likely to come from company specific stories until money starts to flow back into these as a group. As oversold as they are, that could happen at any time. Regarding UUUU, specifically, I think the stock will trade much higher once they get the rare earth purification set up on their site, but that probably isn’t going to happen in the next six months. So, the near-term moves in UUUU will be connected to the price of uranium. I’m aware my credibility took a precipitous drop when IBRX ran to 45 and, today, has tumbled to 6.70. Am going to do a better job of taking some money off the table when there’s a big run up (looking at you IBRX) by selling a little stock or writing calls out above a portion of the position. What made IBRX tough to call was the company had (and still has) an enormous clinical trial pipeline and the stock had run without any news other than the merger of NantKwest and ImmunityBio. It led me to believe the company had imminent news of a drug approval. Next time, I’m taking some profits on the way up and, yes, I think there will be a next time. Holding 33,000 shrs of UUUU @ $5.99, 27,800 shrs of IBRX @ $9.77, and 150,000 shrs of AMYZF @ .85.